HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through its ambulatory 3D ECG platform, announced that it will hold a conference call on August 13 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and provide strategic updates. The call will be led by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, and will include a question-and-answer session following prepared remarks.
The company is dedicated to advancing the detection and monitoring of critical cardiac conditions with its innovative cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions. The platform synthesizes these signals into a 12-lead ECG, enabling physicians to identify cardiac health trends and acute conditions outside of medical facilities. HeartBeam’s technology received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology.
This announcement highlights HeartBeam’s progress toward redefining cardiac health management by enabling portable, patient-centric monitoring. The upcoming call will provide investors with insights into the company’s financial performance and its strategy for expanding global adoption of its platform. For more details, the full press release is available at https://ibn.fm/sqGLs. Additional information about HeartBeam can be found in the company’s newsroom at https://ibn.fm/BEAT.
The company’s cleared indications for use, including the 12-lead ECG synthesis software for arrhythmia assessment, are detailed at https://www.heartbeam.com/indications. As HeartBeam continues to innovate in cardiac care, the upcoming conference call represents a key opportunity for stakeholders to understand the company’s trajectory and the potential impact of its technology on the healthcare landscape.
